Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2+ High-risk Non-muscle-invasive Bladder Cancer
NCT05996952Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin in bladder cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: 12-month recurrence-free survival rate, 3-month pathological complete response rate and 1 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05996952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996952.